These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 27109566)
1. Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero(®) to reduce meningococcal group B disease in Germany. Christensen H; Irving T; Koch J; Trotter CL; Ultsch B; Weidemann F; Wichmann O; Hellenbrand W Vaccine; 2016 Jun; 34(29):3412-9. PubMed ID: 27109566 [TBL] [Abstract][Full Text] [Related]
2. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. Pouwels KB; Hak E; van der Ende A; Christensen H; van den Dobbelsteen GP; Postma MJ Hum Vaccin Immunother; 2013 May; 9(5):1129-38. PubMed ID: 23406816 [TBL] [Abstract][Full Text] [Related]
4. Health impact and cost-effectiveness of introducing the vaccine (Bexsero) against MenB disease into the Brazilian immunization programme. Moura Silveira M; McBride AJA; Trotter CL Vaccine; 2019 Oct; 37(45):6783-6786. PubMed ID: 31570182 [TBL] [Abstract][Full Text] [Related]
6. Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup B Invasive Meningococcal Disease. Scholz S; Schwarz M; Beck E; Meszaros K; Schneider M; Ultsch B; Greiner W Infect Dis Ther; 2022 Feb; 11(1):367-387. PubMed ID: 34877641 [TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732 [TBL] [Abstract][Full Text] [Related]
8. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis. Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398 [TBL] [Abstract][Full Text] [Related]
9. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease. Watson PS; Turner DP Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570 [TBL] [Abstract][Full Text] [Related]
10. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Christensen H; Hickman M; Edmunds WJ; Trotter CL Vaccine; 2013 May; 31(23):2638-46. PubMed ID: 23566946 [TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of meningococcal serogroup B (MenB) vaccines: A systematic review. Nwogu IB; Jones M; Langley T Vaccine; 2021 Apr; 39(16):2201-2213. PubMed ID: 33744052 [TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of 4CMenB Infant Vaccination in England: A Comprehensive Valuation Considering the Broad Impact of Serogroup B Invasive Meningococcal Disease. Beck E; Klint J; Neine M; Garcia S; Meszaros K Value Health; 2021 Jan; 24(1):91-104. PubMed ID: 33431159 [TBL] [Abstract][Full Text] [Related]
13. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218 [No Abstract] [Full Text] [Related]
14. [Economic evaluation of the introduction of 4CMenB (Bexsero®) in the national vaccine schedule in Spain]. Ruiz-Montero R; Epstein D; Guzmán Herrador B; Espín Balbino J Gac Sanit; 2020; 34(4):318-325. PubMed ID: 31776044 [TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City. Simon MS; Weiss D; Geevarughese A; Kratz MM; Cutler B; Gulick RM; Zucker JR; Varma JK; Schackman BR J Acquir Immune Defic Syndr; 2016 Feb; 71(2):146-54. PubMed ID: 26334735 [TBL] [Abstract][Full Text] [Related]
16. Epidemiological impact and cost-effectiveness of universal meningitis b vaccination among college students prior to college entry. Chung GS; Hutton DW PLoS One; 2020; 15(10):e0239926. PubMed ID: 33035260 [TBL] [Abstract][Full Text] [Related]
17. Potential impact of vaccination against Neisseria meningitidis on Neisseria gonorrhoeae in the United States: results from a decision-analysis model. Régnier SA; Huels J Hum Vaccin Immunother; 2014; 10(12):3737-45. PubMed ID: 25483706 [TBL] [Abstract][Full Text] [Related]
18. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme. Tirani M; Meregaglia M; Melegaro A PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805 [TBL] [Abstract][Full Text] [Related]
19. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE; Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206 [TBL] [Abstract][Full Text] [Related]
20. Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands. Hepkema H; Pouwels KB; van der Ende A; Westra TA; Postma MJ PLoS One; 2013; 8(5):e65036. PubMed ID: 23741448 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]